This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Greenberg, D. Articles by Cohen, D. J. Search for Related Content PubMed PubMed Citation Articles by Greenberg, D. Articles by Cohen, D. J.

Can we afford to eliminate restenosis?

Can we afford not to?

Dan Greenberg, PhD^*, Ameet Bakhai, MD, MRCP^* and David J. Cohen, MD, MSc^*,*

^* Harvard Clinical Research Institute, Boston, Massachusetts, USA
Division of Cardiology, Beth Israel–Deaconess Medical Center, Boston, Massachusetts, USA
Clinical Trials and Evaluation Unit, Royal Brompton Hospital, London, United Kingdom

View larger version (16K): [in a new window]   Figure 1 Relationship between the rate of TVR with bare metal stent implantation and the incremental cost-effectiveness of drug-eluting stent implantation for patients undergoing single-vessel percutaneous coronary intervention. Basic assumptions of the cost-effectiveness model are described in the text. The model projects that drug-eluting stent implantation will be reasonably cost-effective (i.e., cost-effectiveness ratio <$10,000/repeat revascularization avoided) for patients with an expected bare metal stent TVR rate >12% and cost-saving for patients with TVR >20%.